Greenwich LifeSciences, Inc. (GLSI) Stock Forecast
GLSI analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 2 analysts
- Price target
- $57.00 average of analyst targets
- Upside to target
- +291.8% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.34
- 52-week range
- $7.85 – $33.56
GLSI analyst ratings
2 analystsNumber of analysts at each rating.
GLSI price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
GLSI earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.37 | −$0.30 | −$0.30 | −11.7% | 2 |
| Current fiscal year (2026) | −$1.39 | −$1.48 | −$1.29 | −$1.43 | +3.1% | 2 |
| Next fiscal year (2027) | −$1.17 | −$1.17 | −$1.17 | −$1.39 | +15.5% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
GLSI revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 2 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 2 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 1 |
GLSI EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
GLSI EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.34 | −$0.34 | −$0.37 | −$0.37 | −$0.34 | 0.0% | 0 up · 0 down |
| Current fiscal year (2026) | −$1.35 | −$1.35 | −$1.48 | −$1.48 | −$1.39 | +2.6% | 0 up · 0 down |
| Next fiscal year (2027) | $0.00 | $0.00 | $0.00 | $0.00 | −$1.17 | — | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
GLSI earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; GLSI beat in 7 of 12.
What analysts expect from GLSI
2 analysts cover Greenwich LifeSciences; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $57.00, 291.8% above the latest close of $14.55. Analysts expect earnings of −$1.39 per share for 2026, +3.1% from a year earlier. For 2027 the average estimate is −$1.17 per share. Greenwich LifeSciences beat the EPS estimate in 7 of the last 12 quarters.
Related: GLSI income statement, GLSI key metrics, GLSI chart. See the GLSI stock overview for the latest quote and news.
GLSI forecast FAQ
What is Greenwich LifeSciences's price target?
The average analyst price target for Greenwich LifeSciences is $57.00, 291.8% above the latest close of $14.55.
Is Greenwich LifeSciences a buy, hold or sell?
Of 2 analysts covering Greenwich LifeSciences, 2 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Greenwich LifeSciences's EPS forecast?
Analysts forecast −$1.39 per share for 2026 (range −$1.48 to −$1.29); for 2027 the estimate is −$1.17.
When does Greenwich LifeSciences report earnings?
Greenwich LifeSciences is expected to report results for the quarter ending September 30, 2026 on November 13, 2026; the EPS estimate is $-0.34.
Does Greenwich LifeSciences usually beat earnings estimates?
Greenwich LifeSciences reported EPS at or above the analyst estimate in 7 of the last 12 quarters.